China Approves Xian-Janssen’s Invega Schizophrenia Treatment
This article was originally published in PharmAsia News
Executive Summary
China's State FDA approved Xian-Janssen Pharmaceutical's Invega, (paliperidone) for the treatment of schizophrenia in China. The formulation is a 24-hour sustained-release tablet. U.S. FDA approved Invega in December 2006 for the treatment of schizophrenia in the United States, and it was then approved in Europe and Asia. Clinical trials indicate that Invega is effective in controlling symptoms associated with schizophrenia including improving social function in patients with the illness (Click here for more)